These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 26223461)

  • 1. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
    Carlo-Stella C; Santoro A
    Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
    Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
    J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
    van den Berg A; Visser L; Poppema S
    Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
    Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML
    Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare expression of T-cell markers in classical Hodgkin's lymphoma.
    Tzankov A; Bourgau C; Kaiser A; Zimpfer A; Maurer R; Pileri SA; Went P; Dirnhofer S
    Mod Pathol; 2005 Dec; 18(12):1542-9. PubMed ID: 16056244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
    Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
    J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
    Montanari F; Diefenbach CS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab in classical Hodgkin's lymphoma.
    Maly J; Alinari L
    Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma.
    Tzankov A; Zimpfer A; Went P; Maurer R; Pileri SA; Geley S; Dirnhofer S
    Mod Pathol; 2005 Jan; 18(1):90-6. PubMed ID: 15389259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in relapsed classical hodgkin lymphoma.
    Dinner S; Advani R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant FHIT protein expression in classical Hodgkin's lymphoma: a potential marker.
    Zhao P; Lam AK; Lu YL; Zhong M; Chen LH; Pu XL
    Pathology; 2006 Oct; 38(5):399-402. PubMed ID: 17008276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
    Younes A; Ansell SM
    Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of K-1 (CD-30) marker in Hodgkin's disease.
    Shakoor KA; Saleh A; Khanzada MS
    J Pak Med Assoc; 2002 Oct; 52(10):442-7. PubMed ID: 12553671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.
    Doussis-Anagnostopoulou IA; Talks KL; Turley H; Debnam P; Tan DC; Mariatos G; Gorgoulis V; Kittas C; Gatter KC
    J Pathol; 2002 Aug; 197(5):677-83. PubMed ID: 12210089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.